Tradestie Institutional Equity Comparison Engine
SRZN vs LEXX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SRZN Overall Edge
SRZN Captures Institutional Edge (2โ1 Pillars ยท 7โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Surrozen, Inc. Common (SRZN) driven by superior Growth & Margin, Options & Structure while LEXX counters with relative strength in Momentum & Technical. Fundamentally, SRZN trades at N/M Forward P/E with -485.4% operating margin (+408.6% YoY revenue) versus LEXX at N/M Forward P/E and -3862.9% operating margin (-88.5% YoY). In options structure, SRZN sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro) against LEXX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
SRZN N/M vs LEXX N/M Fwd P/E
Growth & Margin Winner
SRZN
Op Margin -485.4% vs -3862.9% ยท YoY +408.6% vs -88.5%
Momentum & Technical Winner
LEXX
1Y +166.7% vs +300.9% ยท 52W Pos 79% vs 29%
Options & Structure Winner
SRZN
CONSOLIDATION (5th %ile IV) vs UNCLASSIFIED (N/A IV)
SRZN
NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$32.32
+2.25% 1D
Market Cap
$602.5M
1M Return
+37.88%
1Y Return
+166.67%
Forward P/E
N/M
Unified AI Score
34.3 / 100
SELL
Tech 5.0
Fund 32.0
Flow 65.0
Mom 40.0
LEXX
NASDAQ
Lexaria Bioscience Corp. Common Stock
Pharmaceutical Preparations
$4.41
-0.68% 1D
Market Cap
$9.4M
1M Return
+54.2%
1Y Return
+300.91%
Forward P/E
N/M
Unified AI Score
33.3 / 100
SELL
Tech 50.0
Fund 30.0
Flow 50.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
SRZN +166.67%
LEXX +300.91%
Spread: +134.24 pp (LEXX Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SRZN Revenue | LEXX Revenue | SRZN Op. Margin | LEXX Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $0M | N/A | -1525.4% | LEXX |
| FY2019 | N/A | $0M | N/A | -1868.0% | LEXX |
| FY2020 | N/A | $0M | N/A | -1062.2% | LEXX |
| FY2021 | N/A | $0M | N/A | -786.8% | LEXX |
| FY2022 | $10M | $0M | -354.7% | -2591.7% | SRZN |
| FY2023 | N/A | $0M | N/A | -2888.5% | LEXX |
| FY2024 | $10M | $0M | -239.7% | -1239.2% | SRZN |
| FY2025 | $0M | $0M | -1210.6% | -1683.0% | SRZN |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | SRZN | LEXX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $602.5M | $9.4M | Larger Scale | SRZN |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +408.6% | -88.5% | Higher Growth | SRZN |
| Operating Margin (TTM) Profitability | -485.4% | -3862.9% | Higher Margin | SRZN |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -62.8% | -162.8% | Higher ROE | SRZN |
| 52-Week Range Position Momentum | 79% ($12โ$38) | 29% ($0โ$14) | Stronger Trend | SRZN |
| Beta / 30D Volatility Risk Regime | 1.21ฮฒ ยท 62% Vol | 11.09ฮฒ ยท 92% Vol | Lower Realized Risk | SRZN |
| Unified Institutional Score Composite Signal | 34.3 / 100 (SELL) | 33.3 / 100 (SELL) | Higher Composite | SRZN |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full SRZN vs LEXX Buy Guide
SRZN
CONSOLIDATION
37d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
5th %ile
IV Regime
Compressed (<25th %ile)
LEXX
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither SRZN nor LEXX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.